CXW vs DCO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CXW presents a stable financial profile with a Piotroski F-Score of 4/9 and a valuation that sits comfortably between its Graham Number ($18.47) and Intrinsic Value ($31.86). The company is exhibiting aggressive growth, with YoY earnings growth of 42.4% and a highly attractive forward P/E of 9.93. While technical trends and insider sentiment are currently bearish, the strong earnings beat track record and analyst consensus suggest significant upside potential. The overall profile is that of a growth-oriented value play within a specialized industrial niche.
DCO presents a stark contrast between operational momentum and fundamental financial health, highlighted by a weak Piotroski F-Score of 3/9. While the company boasts an exceptional earnings beat track record and strong liquidity (Current Ratio 3.50), the negative net profit margin (-4.11%) and negative ROE (-5.05%) are significant concerns. The stock has experienced a massive 147% rally over the last year, pushing it near its 52-week high, yet insider sentiment is bearish with significant selling by the CFO and Directors. The disconnect between the 'Strong Buy' analyst consensus and the deteriorating deterministic health scores suggests the current price is driven by growth expectations rather than current financial stability.
Compare Another Pair
Related Comparisons
CXW vs DCO: Head-to-Head Comparison
This page compares CoreCivic, Inc. (CXW) and Ducommun Incorporated (DCO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.